Thalidomide was withdrawn from the market in the early sixties because of major 
teratogenic effects such as reduction defects of the limbs. Since, however, it 
has been found to be an effective drug in erythema nodosum leprosum. In the 
United States it was decided in September 1997 to admit thalidomide to the 
market for this indication, and in South America it has been available for this 
indication all the time. Thalidomide is also efficacious in other major 
disorders (e.g. aphtae and ulcers in aids) or its efficacy is being investigated 
in clinical trials (e.g. autoimmune diseases, other complications in aids). The 
American Food and Drug Administration has imposed conditions for the use of 
thalidomide. Users have to sign an informed consent and to take adequate 
contraceptive measures. Physicians should inform the patients and monitor side 
effects. Pharmacists should record and control the use.